A Trial of 2 Disease-Modifying Drugs (Metformin and N-acetylcysteine ) to Promote TB Lung Function Recovery

Tuberculosis is a leading global cause of morbidity and mortality. Even if cured, a majority patients are left with bronchiectasis and fibrosis, permanent conditions that impair lung function. Large cohort studies have confirmed that even modest loss of lung function is associated with excess mortality risk. This study will examine if two treatments, metformin and N-acetylcysteine (NAC), can promote the recovery of lung function in TB if given together with standard TB treatment. There currently are no drugs approved for this indication.

NCT Number	NCT07136987
Lead Sponsor	Open Source Pharma Foundation Collaborators: National Institute for Research in Tuberculosis, Chennai, India
Conditions	Tuberculosis
Enrollment	1,104 participants
Start Date	2026-01
Primary Completion	2031-01 (estimated)
Study Completion	2031-07 (estimated)
Updated on ClinicalTrials.gov	2025-08-22